• Product NameSGX-523
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivitySGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1.
• Target NameBcr-Abl inhibitor; c-Met/HGFR inhibitor; p38 MAPK inhibitor; Raf inhibitor
• CAS No. 1022150-57-7
• Calculated MW 359.41
• Formulation C18H13N7S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1C=C(C=N1)C1=NN2C(SC3=CC4=C(C=C3)N=CC=C4)=NN=C2C=C1
  Pathways:Angiogenesis; MAPK; Tyrosine Kinase/Adaptors; Cytoskeletal Signaling
  Receptor:Abl; c-Met; p38α; B-Raf (V599E); C-Raf
  Boling pt:
  Melting pt:
  Solubility:DMSO: 2 mg/mL (5.56 mM)
  Appearance:Faint Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Buchanan SG, et al. Mol Y Ther, 2009, 8(12), 3181-3190.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting